See this post first.... https://piotrpeterblog.com/2021/05/18/morbidity-and-disability-in-phase-2a-alzheimers-study-of-blarcamsine-vs-background-morbidity-in-similar-age-control-group-avxl/ Now to the Chart. I will be on a 12 days vacations so might not post anything so I need a more beer money .... Make a one-time donationYour contribution is appreciated.DonateMake a monthly donationYour contribution is appreciated.Donate monthlyMake a yearly donationYour contribution is appreciated.Donate yearly
$SAVA Success Wave Lifting All Boats The released $SAVA data brought about a wave of investment and renewed vigour to investing into smaller Alzheimer's narratives. When most of the news is just shadowing the declines and any number above the initail score is reason for hope. A couple of things are transpiring among the companies … Continue reading Who is Following Whose Success? $SAVA $ANVS $AVXL
A Battle in Etiology Wars! The most prevalent hypothesis of the etiologies of Alzheimer's disease is the A-Beta Amyloid deposits theory. The theory has been evolving into few branches. One of them states that there is production of A-beta in the axions of neurons in response to stress and the toxicity of A-beta works its … Continue reading The Alzheimer’s Etiology Wars! $AVXL $ANVS
I would like to add some additional information to the previously presented analysis on the dropout rate after 5 years. Though the number of remaing subjects in the Phase2a OLE and Humanitarian Extension is rather imprecise as Dr. Missling put it between 21 and 10, I used as reference paper titled Variability in Annual Mini-Mental … Continue reading Morbidity and Disability in Phase 2a Alzheimer’s Study of Blarcamsine vs. Background Morbidity in Similar Age Control Group $AVXL
On the 13th of May 2021, Dr Missling had conference call on the Q1 2021 results. The call was very brief but the questions from analysts were more detailed and aimed at elucidating future prospects of the company. One was of interest to me over immediate promises. Namely, question about dropout rate in Phase2a Alzheimer's … Continue reading Anavex Life Sciences Alzheimer’s Phase2a Dropout in Light of Info from Conference Call Q1 2021 Blarcamesine $AVXL
SIGMAR1 Agonists - Therapeutic Swiss Army Knives My intention is to call on a paper which unravels the mystery of mechanism of action of the SIGMAR1 receptor agonists, among them is Blarcamesine ($AVXL) and Pridopidine from Prilenia Therapeutics Development LTD. The paper in question is titled  Sigma-1 Receptor (S1R) Interaction with Cholesterol: Mechanisms of … Continue reading SIGMAR1 Agonists – Therapeutic Swiss Army Knives $AVXL, Prilenia Therapeutics, $ATHA, $ALKS, $SAVA
https://youtu.be/2udndGQa4DY This is a video I had made few months ago.